CURRENT AFFAIRS

Detailed explanation-1: -GSK first unveiled its ambitions in bioelectronics three years ago. London: GlaxoSmithKline and Alphabet’s life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a new field of medicine known as bioelectronics.

Detailed explanation-2: -Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck.

Detailed explanation-3: -Now, a new name for GlaxoSmithKline’s consumer health unit? Also check. Haleon, pronounced “Hay-Lee-On, ” will be GSK Consumer Health’s new name once it spins off from the group and debuts as a standalone company mid-2022, GSK unveiled Tuesday.

Detailed explanation-4: -We make innovative vaccines and specialty medicines to prevent and treat disease. Our R&D focuses on the science of the immune system, human genetics and advanced technologies. Our R&D focus is on four therapeutic areas: infectious diseases, HIV, oncology, and immunology. Why invest in GSK?

Detailed explanation-5: -GSK’s consumer health business has been a joint venture with Pfizer. Prior to the two companies forming a consumer health partnership, GSK had once been a contender to acquire Pfizer’s consumer health business.